Physicians’ Prescription Behaviour: An Empirical Study of in the Context of Critical Diseases

Authors

  • JYOTSANA BHATT Assistant Professor,Department of Pharmacy , Graphic Era Hill University, Dehradun Uttarakhand India 248002 Author

DOI:

https://doi.org/10.61841/hzm3k934

Keywords:

Physician prescription behavior, critical diseases, patient-related factors, disease-related factors, pharmaceutical company-related factors, physician-related factors, medical education

Abstract

 This study aims to investigate the various parameters that cause several inclinations physicians' prescription behavior in the context of critical diseases. Patient-related factors, such as patients' socioeconomic status and insurance coverage significantly influence physicians' prescription behavior. Additionally, disease-related factors, such as the severity of the disease and the complexity of the treatment regimen also impact physicians' prescription behavior. Pharmaceutical company-related factors, such as drug marketing and promotional activities, also play a crucial role in influencing physicians' prescription behavior. Finally, physicianrelated factors, such as their experience and medical education, were found to influence prescription behavior. Overall, the study provides valuable insights into the complex nature of physicians' prescription behavior in the context of critical diseases, highlighting the importance of various factors that influence this behavior. 247 people were surveyed to know the factors influencing prescription behaviour of physicians. These findings have important implications for healthcare policymakers, medical professionals, and pharmaceutical companies, as they provide insight into how best to address the various factors that influence prescription behavior and optimize treatment outcomes for critical diseases. 

Downloads

Download data is not yet available.

References

• Balasubramanian, N., Ganeshkumar, P., & Kattimani, S. (2016). Physician-industry

interaction: Healthcare professionals’ perception of conflicts of interest in India. Indian

Journal of Medical Ethics, 1(2), 66-71.

• Chatterjee, P., Biswas, T., & Datta, A. (2018). Promotion and prescription practices of

pharmaceutical drugs: A study among physicians in a tertiary-care hospital in Kolkata.

Journal of Education and Health Promotion, 7, 54.

• Dellit, T. H., Owens, R. C., McGowan Jr, J. E., Gerding, D. N., Weinstein, R. A., Burke,

J. P., ... & IDSA/SIS/APIC Guidelines Committee (2007). Infectious Diseases Society

of America and the Society for Healthcare Epidemiology of America guidelines for

developing an institutional program to enhance antimicrobial stewardship. Clinical

Infectious Diseases, 44(2), 159-177.

• Hassali, M. A., Kong, D. C. M., & Stewart, K. (2012). Generic medicines: Perceptions

of physicians in selected hospitals in Penang, Malaysia, and their prescribing patterns.

The Australasian Medical Journal, 5(8), 436-442.

• Kesselheim, A. S., Misono, A. S., Lee, J. L., Stedman, M. R., Brookhart, M. A.,

Choudhry, N. K., & Shrank, W. H. (2016). Clinical equivalence of generic and brandname drugs used in cardiovascular disease: A systematic review and meta-analysis.

Journal of the American Medical Association, 315(16), 1720-1730.

• Knapp, H., Anzueto, A., Criner, G. J., Kelsen, S., & Martinez, F. J. (2014). Physician

perspectives on the management of COPD. International journal of chronic obstructive

pulmonary disease, 9, 1269–1282. https://doi.org/10.2147/COPD.S66725

• Mashamba-Thompson, T. P., Sartorius, B., Sartorius, K., & Choonara, Y. (2017).

Patients’ perspectives on generic medicines in South Africa: A qualitative study using

focus groups and semi-structured interviews among human immunodeficiency virus

infected adults. Journal of Pharmaceutical Policy and Practice, 10(1), 24.

https://doi.org/10.1186/s40545-017-0114-4

• Norris, S. L., Holmer, H. K., Ogden, L. A., Burda, B. U., Fu, R., & Bero, L. A. (2013).

Characteristics of physicians receiving large payments from pharmaceutical companies

and the accuracy of their disclosures. JAMA, 309(4), 357-359.

https://doi.org/10.1001/jama.2012.116585

• Persaud, N., Lee, T., Ahmad, M., Li, W., Taglione, M. S., & Jain, S. (2012). Informed

public opinion on the use of generic drugs. Canadian Family Physician, 58(8), e460-

e466. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3419239/

• Shrank, W. H., Cox, E. R., Fischer, M. A., Mehta, J., Choudhry, N. K., & Gleason, P.

P. (2011). Patients’ perceptions of generic medications. Health Affairs, 30(11), 2151-

2157. https://doi.org/10.1377/hlthaff.2011.0290

• Shrank, W. H., Liberman, J. N., Fischer, M. A., Girdish, C., Brennan, T. A., &

Choudhry, N. K. (2009). Physician perceptions about generic drugs. Annals of

Pharmacotherapy, 43(6), 1006-1011. https://doi.org/10.1345/aph.1L566

• Spurling, G. K., Mansfield, P. R., Montgomery, B. D., & Lexchin, J. (2010).

Information from pharmaceutical companies and the quality, quantity, and cost of

physicians' prescribing: a systematic review. PLoS medicine, 7(10), e1000352.

https://doi.org/10.1371/journal.pmed.1000352

• Steinman, M. A., Shlipak, M. G., McPhee, S. J., & Ofman, J. J. (2006). Narrative

review: The promotion of gabapentin: An analysis of internal industry documents.

Annals of Internal Medicine, 145(4), 284-293

Downloads

Published

28.02.2021

How to Cite

BHATT, J. (2021). Physicians’ Prescription Behaviour: An Empirical Study of in the Context of Critical Diseases. International Journal of Psychosocial Rehabilitation, 25(1), 694-702. https://doi.org/10.61841/hzm3k934